![2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine图片](http://www.cnreagent.com/data/daily/2022/12/02/170443_992163_umcs_1047296.png)
| CAS NO: | 133240-06-9 |
| 包装 | 价格(元) |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Cas No. | 133240-06-9 |
| 别名 | 咪唑并二甲基吡啶 |
| 化学名 | 2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine |
| Canonical SMILES | CC1=CC(C)=C2C(N1)=NC(CC)=N2 |
| 分子式 | C10H13N3 |
| 分子量 | 175.2 |
| 溶解度 | ≥ 5.3mg/mL in DMSO |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | 2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine is a nonpeptidic angiotensin II receptor antagonist. Angiotensin II is the critical pressor substance of the renin-angiotensin system (RAS). The angiotensin II system, a proteolytic cascade regulating hemodynamics and water and electrolyte balance, is able to contribute to hypertensive states in human. The effects of the octapeptide angiotensin I1 includs cardiac stimulation, vasoconstriction, stimulation of aldosterone synthesis and release, as well as renal reabsorption of sodium. In vitro: In a previous study, 2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine was synthezed by reduction of 2-amino-3-nitropyridine derivatives to the corresponding diaminopyridine which was then condensed with an appropriate carboxylic acid in polyphosphoric acid. In vitro activity study showed that 2-Ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine was a nonpeptidic angiotensin II receptor antagonist whose imidazo[4,5-b]pyridine scaffold had been used to examine plenty of positional substitutions in the development of orally active, long duration antihypertensive agents [1]. In vivo: Up to now, there is no animal in vivo data reported. Clinical trial: So far, no clinical study has been conducted. Reference: |
m.cnreagent.com